Health · Pharma & Biotech · 2 days ago
Early research links GLP-1 drugs to slower molecular aging
Researchers at Novo Nordisk and Eli Lilly say their GLP-1 drugs may slow some molecular changes associated with aging.
They presented findings on semaglutide, sold as Ozempic and Wegovy, and tirzepatide, sold as Mounjaro and Zepbound, at an aging research conference.
In analyses of clinical trial data, people taking the drugs showed slower aging on certain molecular measures than people given a placebo.
Most of the semaglutide measures suggested a slowdown of two to three years, though results varied by measure and organ.
The research is preliminary, has not been peer-reviewed, and was conducted by scientists at the companies that make the drugs.
It is not yet clear whether changes in these measures lead to longer or healthier lives, and the studies focused on people with obesity or type 2 diabetes.
A federally funded trial will study whether GLP-1s and other drugs can extend longevity and healthy aging in people over 60.
Researchers from Novo Nordisk and Eli Lilly reported that their GLP-1 drugs were linked to slower biological aging in analyses presented at a conference.
The studies found changes in molecular or epigenetic aging markers compared with placebo or control groups.
Most clocks in the semaglutide analysis showed a slowdown of two to three years, while one heart-protein clock showed roughly four years.
The findings are preliminary, have not undergone peer review and were produced by scientists working for the drug companies.
Researchers have not established whether changes in aging clocks translate into tangible health benefits.
- Who
- Scientists from Novo Nordisk and Eli Lilly studied people taking semaglutide and tirzepatide.
- What
- Their analyses linked the drugs to slower biological aging, measured through molecular or epigenetic clocks.
- When
- The findings were presented the weekend before the article was published on October 9, 2026.
- Where
- At the 13th annual Aging Research & Drug Discovery conference.
- Why
- The researchers examined whether the drugs affected markers associated with aging. The reason for any effect is not established.
This story does not have two clearly opposing sides.
All the clocks are telling a consistent story that we’re seeing a reduction in age
It’s not like we’re going to reverse age by 30 years or something, but it’s a significant reduction.
Novo Nordisk scientists analyzed existing clinical trial data on semaglutide, while Eli Lilly scientists analyzed epigenetic data on tirzepatide.
Both companies presented their findings at the 13th annual Aging Research & Drug Discovery conference.
The federal government was funding a trial to study whether GLP-1s and other drugs can extend longevity and healthy aging in people over 60.
- Semaglutide analysis
- Most clocks showed a slowdown of two to three years compared with placebo.
- Heart-related clock
- One clock based on heart-related proteins showed a slowdown of roughly four years.
- Tirzepatide analysis
- Eli Lilly scientists assessed epigenetic clocks.
- Conference
- 13th annual Aging Research & Drug Discovery conference.
- Future trial
- Federal funding supports a trial involving people over 60.
Sources
Related news
Bristol Myers lung disease drug meets main goal in late-stage trial
Experimental Cream Shows Early Signs of Reducing Skin Aging
FDA approves first new oral antiviral for resistant herpes in nearly 30 years
GLP-1 drugs show potential benefits for heart and metabolic health
FDA approves atezolizumab with chemotherapy for some stage III colon cancers
Review links drug company gifts to more and less appropriate prescribing
Brazil suspends Peptistrong supplement and orders all batches recalled
Idorsia presents new findings on blood pressure drug aprocitentan
Personalized cancer vaccine succeeds in phase 3 melanoma trial
Study links GLP-1 drug use with more reported nail problems
Pilot trial tests support to limit weight regain after GLP-1 drugs stop
